CN107648313A - A kind of Western medicine compound for treating obesity and preparation method thereof - Google Patents
A kind of Western medicine compound for treating obesity and preparation method thereof Download PDFInfo
- Publication number
- CN107648313A CN107648313A CN201711093416.2A CN201711093416A CN107648313A CN 107648313 A CN107648313 A CN 107648313A CN 201711093416 A CN201711093416 A CN 201711093416A CN 107648313 A CN107648313 A CN 107648313A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- carrotene
- acid
- orlistat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to pharmaceutical technology field, specifically discloses a kind of Western medicine compound for treating obesity and preparation method thereof, counts in parts by weight, including following components：8 12 parts of 60 120 parts of orlistat, 10 25 parts of fiery sesame oil, 10 15 parts of soyabean protein powder, 10 25 parts of evening primrose oil, 5 10 parts of linoleic acid, 10 15 parts of citric acid, 5 15 parts of β-carrotene, 3 10 parts of vitamin D, 3 10 parts of vitamin E, 3 10 parts of vitamin K, 5 10 parts of xylitol and tartaric acid.The composition of the present invention, accelerate the obstinate adipose tissue hoarded in consumer while the intake of new fats is blocked, and supplement the loss of other trace nutrients in weight loss procedures in time, reach the effect of safe fat-reducing.
Description
Technical field
The invention belongs to field of medical technology, and in particular to a kind of Western medicine compound for treating obesity and its preparation side
Method.
Background technology
The World Health Organization has confirmed that obesity is a kind of disease, and global obesity patient was just doubled with about 5 years
Trend it is increasing, shared overweight people at least as many as 2-5 hundred million in the whole world at present, the people of super severe one about 1,000,000,000.China surpasses for more than 20 years old
Severe one about 300,000,000, for overweight people more than 40,000,000, obesity increases " three often along with " three high " (hypertension, hyperglycaemia, high fat of blood)
The chance of disease " (diabetes, heart disease, cancer).Diabetes patient more than 80% has fat history, and more than 90% can concurrent cardiovascular and cerebrovascular
Disease.Increasing research shows that obesity can cause immune function of human body to fail so that obese people turns into cancer people occurred frequently
Group, and cause sexual deterioration and fertility-rate to decline.In addition, often self-doubt and to the opposite sex the attraction of fat people,
So as to cause heavy psychological pressure.
Orlistat (Orlistat), is current globally unique OTC slimming drugs, and the whole world is taken more than 40,000,000 people
And successful weight loss, it is current best-selling diet products.At present, orlistat is in the world uniquely by U.S. FDA, Yi Jiwo
The slimming drugs of food and medicine Surveillance Authority of state approval.It is a kind of potent and long-acting specific gastrointestinal fat enzyme level
Agent, by directly blocking human body, to absorption fatty in food, once the heat energy of intake is with fat less than consumption, and body fat is certainly
So reduce, so as to reach the purpose of loss of weight.It is safe fat-reducing, and active ingredient does not enter blood circulation, does not act on maincenter god
Through, side effect is less, be not in it is dizzy, nervous, insomnia, dry situations such as.
But as the slimming medicine for uniquely going through to use, the defects of orlistat still has it, be mainly manifested in
Lower three aspects：1) research shows that the loss of liposoluble vitamin can be caused by taking orlistat；2) it is difficult to understand during fat reducing
Li Sita has blocked the heat and fat of new intake, while also prevents the intake of essential fatty acid, causes the patient that loses weight
The adverse reactions such as weary body, drowsiness, dry skin, hypoevolutism are produced when taking orlistat；3) orlistat is external source
Property the intake for reducing fat, decomposing itself existing fat, in terms of particularly reducing lipids contents, orlistat can not
Play a role and help patient to decompose own fat, decrease blood lipid content, it is necessary to take other compositions simultaneously.
The content of the invention
In order to solve the above problems, the present invention provides a kind of Western medicine compound for treating obesity and preparation method thereof, this
The composition of invention, the obstinate adipose tissue hoarded while the intake of new fats is blocked in acceleration consumer, and and
When supplement the losses of other trace nutrients in weight loss procedures, reach the effect of safe fat-reducing.
The present invention is only applicable to Simple Obesity Patient, there is other diseases or hepatic and kidney function obstacle person disabling.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：A kind of Western medicine compound for treating obesity, by weight
Measure fraction meter, including following components：Orlistat 60-120 parts, fiery sesame oil 10-25 parts, soyabean protein powder 10-15 parts, oenothera biennis
Oily 10-25 parts, linoleic acid 5-10 parts, citric acid 10-15 parts, β-carrotene 5-15 parts, vitamin D 3-10 parts, vitamin E
3-10 parts, vitamin K 3-10 parts, xylitol 5-10 parts and tartaric acid 8-12 parts.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Preferably, a kind of Western medicine compound for treating obesity, by weight fraction meter, including following components：Orlistat
80-100 parts, fiery sesame oil 15-20 parts, soyabean protein powder 12-14 parts, evening primrose oil 15-20 parts, linoleic acid 6-8 parts, citric acid
12-14 parts, β-carrotene 8-12 parts, vitamin D 5-8 parts, vitamin E 5-8 parts, vitamin K 5-8 parts, xylitol 6-8
Part and tartaric acid 9-11 parts.
The present invention also provides a kind of preparation method for the Western medicine compound for treating obesity, it is characterised in that including following
Step：
Step 1：Count in parts by weight, take following raw material：Orlistat 80-100 parts, fiery sesame oil 15-20 parts, soybean protein
Powder 12-14 parts, evening primrose oil 15-20 parts, linoleic acid 6-8 parts, citric acid 12-14 parts, β-carrotene 8-12 parts, vitamin D
5-8 parts, vitamin E 5-8 parts, -8 parts of vitamin K5, xylitol 6-8 parts and tartaric acid 9-11 parts；
Step 2：β-carrotene, vitamin D, vitamin E, vitamin K is taken to be added to nonmetallic mortar in desinfection chamber
In grind well 10-15 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, take linoleic acid, citric acid to add in above-mentioned mortar and grind well 1-3 minutes, closed black out is protected
Deposit standby；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 1-3 minutes, closed black out saves backup；
Step 5：In desinfection chamber, orlistat is added in above-mentioned mortar and grinds well 1-3 minutes, closed black out preserves standby
With；
Step 6：In desinfection chamber, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed
It is even, and 0.3-0.7g piece, grain, ball are pressed into, get product.
Compared with prior art, the beneficial effects of the invention are as follows：
The present invention is by orlistat, β-carrotene, vitamin D, vitamin E, vitamin K, fructus cannabis oil, evening primrose oil
Used as compound formula, liposoluble vitamin caused by effectively compensate for oral orlistat and essential amino acid lack
Lose, so as to reach the purpose of safe fat-reducing.When supplementing fat-soluble A, before replenishing vitamins A
The method of body material --- beta carotene, so as to avoid vitamin A overdose and caused side effect.Fructus cannabis oil is not
Human body can be only helped to discharge enteron aisle rubbish, abundant unrighted acid contained therein can effectively reduce blood fat with phytosterol
Content, scavenger-cell free radical, anti-aging.Evening primrose oil contains a large amount of essential fatty acids, reduces T-CHOL, can pierce
Swash a large amount of obstinate brown adipose tissues for hoarding in vivo, excessive heat in consumer, so as to reach the effect of " combustion fat ".Cause
This, composition of the invention, accelerates the obstinate adipose tissue hoarded in consumer while the intake of new fats is blocked,
And the loss of other trace nutrients in weight loss procedures is supplemented in time, reach the effect of safe fat-reducing.
Embodiment
The principles and features of the present invention are described below, and the given examples are served only to explain the present invention, is not intended to limit
Determine the scope of the present invention.
Embodiment 1：
A kind of preparation method for the Western medicine compound for treating obesity, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：80 parts of orlistat, 15 parts of fiery sesame oil, 14 parts of soyabean protein powder,
20 parts of evening primrose oil, 6 parts of linoleic acid, 12 parts of citric acid, 12 parts of β-carrotene, 8 parts of vitamin D, 5 parts of vitamin E, dimension life
11 parts of plain 5 parts of K, 8 parts of xylitols and tartaric acid；
Step 2：β-carrotene, vitamin D, vitamin E, vitamin K is taken to be added to nonmetallic mortar in desinfection chamber
In grind well 10 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, linoleic acid, citric acid is taken to add in above-mentioned mortar and grind well 3 minutes, closed black out preserves
It is standby；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 1 minute, closed black out saves backup；
Step 5：In desinfection chamber, orlistat is added in above-mentioned mortar and ground well 3 minutes, closed black out saves backup；
Step 6：In desinfection chamber, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed
It is even, and 0.3g ball is pressed into, get product.
Embodiment 2：
A kind of preparation method for the Western medicine compound for treating obesity, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：100 parts of orlistat, 20 parts of fiery sesame oil, soyabean protein powder 12
Part, 15 parts of evening primrose oil, 8 parts of linoleic acid, 14 parts of citric acid, 8 parts of β-carrotene, 5 parts of vitamin D, 8 parts of vitamin E, dimension
Raw 9 parts of plain 8 parts of K, 6 parts of xylitols and tartaric acid；
Step 2：β-carrotene, vitamin D, vitamin E, vitamin K is taken to be added to nonmetallic mortar in desinfection chamber
In grind well 15 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, linoleic acid, citric acid is taken to add in above-mentioned mortar and grind well 1 minute, closed black out preserves
It is standby；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 1 minute, closed black out saves backup；
Step 5：In desinfection chamber, orlistat is added in above-mentioned mortar and ground well 2 minutes, closed black out saves backup；
Step 6：In desinfection chamber, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed
It is even, and 0.5g piece is pressed into, get product.
Embodiment 3：
A kind of preparation method for the Western medicine compound for treating obesity, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：90 parts of orlistat, 17 parts of fiery sesame oil, 13 parts of soyabean protein powder,
18 parts of evening primrose oil, 7 parts of linoleic acid, 13 parts of citric acid, 9 parts of β-carrotene, 6 parts of vitamin D, 6 parts of vitamin E, dimension life
10 parts of plain 6 parts of K, 7 parts of xylitols and tartaric acid；
Step 2：β-carrotene, vitamin D, vitamin E, vitamin K is taken to be added to nonmetallic mortar in desinfection chamber
In grind well 13 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, linoleic acid, citric acid is taken to add in above-mentioned mortar and grind well 3 minutes, closed black out preserves
It is standby；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 2 minutes, closed black out saves backup；
Step 5：In desinfection chamber, orlistat is added in above-mentioned mortar and ground well 1 minute, closed black out saves backup；
Step 6：In desinfection chamber, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed
It is even, and 0.7g piece is pressed into, get product.
Comparative example
A kind of preparation method for the Western medicine compound for treating obesity, it is characterised in that comprise the following steps：
Step 1：Count in parts by weight, take following raw material：Fiery 17 parts of sesame oil, 13 parts of soyabean protein powder, 18 parts of evening primrose oil,
6 parts of 7 parts of linoleic acid, 13 parts of citric acid, 9 parts of β-carrotene, 6 parts of vitamin D, 6 parts of vitamin E, vitamin K xylitols 7
10 parts of part and tartaric acid；
Step 2：β-carrotene, vitamin D, vitamin E, vitamin K is taken to be added to nonmetallic mortar in desinfection chamber
In grind well 13 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, linoleic acid, citric acid is taken to add in above-mentioned mortar and grind well 3 minutes, closed black out preserves
It is standby；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 2 minutes, closed black out saves backup；
Step 5：In desinfection chamber, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed
It is even, and 0.7g piece is pressed into, get product.
The Western medicine compound for implementing 3 treatment obesity to the present invention carries out clinical test, evaluates the medicine of the present embodiment 3
Fat-reducing effect.
1st, case selection：
Choose 160 Simple Obesity Patients, wherein male 69, women 91, by examining, without the obvious heart, liver,
The dysfunctions such as courage, kidney, patient BMI >=30,160 patients are randomly divided into two groups, every group 80, respectively experimental group and right
According to group.
2nd, instructions of taking：
Experimental group takes the medicine of the treatment obesity obtained in the embodiment of the present invention 3, three times per day, one at a time, clothes
The medicine time is 30 days；Control group takes the medicine of the treatment obesity obtained in comparative example of the present invention, three times per day, one time one
Piece, medicine time are 30 days.Original eating habit, normal diet are not changed during experiment.
3rd, curative effect judges：
It is effective：The BMI of patient is down to normal level, and BMI≤25；
Effectively：The BMI of patient is reduced, but not up to standard level.
4th, test result：
The present embodiment treats the medicine of obesity, total effective rate 93.75%, inefficiency 6.25%.Specific data are shown in
Table 1.And after taking medicine, diabetes and the generation of other organic heart diseasies, the generation without other internal medicine serious diseases, blood are not found
Routine urinalysis and hepatic and renal function are normal.
The test result contrast table of table 1
| It is effective | Effectively | It is invalid | Total effective rate | Inefficiency | |
| Experimental group | 40 | 35 | 5 | 93.75% | 6.25% |
| Control group | 25 | 30 | 25 | 68.75% | 31.25% |
As can be seen here, composition total effective rate of the invention is up to 93.75%, adds while the intake of new fats is blocked
The obstinate adipose tissue hoarded in fast consumer, and the loss of other trace nutrients in weight loss procedures is supplemented in time,
Reach the effect of safe fat-reducing.
Claims (3)
1. a kind of Western medicine compound for treating obesity, it is characterised in that fraction meter by weight, including following components：Ao Lisi
His 60-120 parts, fiery sesame oil 10-25 parts, soyabean protein powder 10-15 parts, evening primrose oil 10-25 parts, linoleic acid 5-10 parts, lemon
Sour 10-15 parts, β-carrotene 5-15 parts, vitamin D 3-10 parts, vitamin E 3-10 parts, vitamin K 3-10 parts, xylose
Alcohol 5-10 parts and tartaric acid 8-12 parts.
A kind of 2. Western medicine compound for treating obesity according to claim 1, it is characterised in that fraction meter by weight,
Including following components：Orlistat 80-100 parts, fiery sesame oil 15-20 parts, soyabean protein powder 12-14 parts, evening primrose oil 15-20
Part, linoleic acid 6-8 parts, citric acid 12-14 parts, β-carrotene 8-12 parts, vitamin D 5-8 parts, vitamin E 5-8 parts, dimension
Raw plain K 5-8 parts, xylitol 6-8 parts and tartaric acid 9-11 parts.
3. a kind of a kind of preparation method of Western medicine compound for treating obesity as described in claim 1-2 is any, its feature
It is, comprises the following steps：
Step 1：Count in parts by weight, take following raw material：Orlistat 80-100 parts, fiery sesame oil 15-20 parts, soyabean protein powder
12-14 parts, evening primrose oil 15-20 parts, linoleic acid 6-8 parts, citric acid 12-14 parts, β-carrotene 8-12 parts, vitamin D 5-
8 parts, vitamin E 5-8 parts, vitamin K 5-8 parts, xylitol 6-8 parts and tartaric acid 9-11 parts；
Step 2：Take β-carrotene, vitamin D, vitamin E, vitamin K to be added in nonmetallic mortar in desinfection chamber to grind
Even 10-15 minutes, it is closed be kept in dark place it is standby；
Step 3：In desinfection chamber, take linoleic acid, citric acid to add in above-mentioned mortar and grind well 1-3 minutes, closed black out preserves standby
With；
Step 4：In desinfection chamber, take tartaric acid to add in above-mentioned mortar and grind well 1-3 minutes, closed black out saves backup；
Step 5：In desinfection chamber, orlistat is added in above-mentioned mortar and grinds well 1-3 minutes, closed black out saves backup；
Step 6：In desinfection chambers, soyabean protein powder, xylitol, fiery sesame oil and evening primrose oil are added in above-mentioned mortar and mixed,
And 0.3-0.7g piece, grain, ball are pressed into, get product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093416.2A CN107648313A (en) | 2017-11-08 | 2017-11-08 | A kind of Western medicine compound for treating obesity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711093416.2A CN107648313A (en) | 2017-11-08 | 2017-11-08 | A kind of Western medicine compound for treating obesity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107648313A true CN107648313A (en) | 2018-02-02 |
Family
ID=61120737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711093416.2A Withdrawn CN107648313A (en) | 2017-11-08 | 2017-11-08 | A kind of Western medicine compound for treating obesity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648313A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112690457A (en) * | 2020-12-24 | 2021-04-23 | 石药集团中诺药业（泰州）有限公司 | Nutrient composition formula for overweight and obese people |
-
2017
- 2017-11-08 CN CN201711093416.2A patent/CN107648313A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112690457A (en) * | 2020-12-24 | 2021-04-23 | 石药集团中诺药业（泰州）有限公司 | Nutrient composition formula for overweight and obese people |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103431392B (en) | Composite marine food for special dietary uses for diabetics | |
| CN1846764A (en) | Health medicinal wine | |
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| CN1314422C (en) | Shiweifuzheng medicine for tonifying qi and blood, warning yang and strengthening spleen and its prepn process | |
| CN1814167A (en) | Health-care for diabetes | |
| CN108618126A (en) | A kind of Chinese medicine compound prescription weight-reducing special diet food and preparation method thereof | |
| CN112137115A (en) | Ketogenic nutrition powder with immunity enhancing effect and preparation method thereof | |
| CN107467315A (en) | A kind of tea for reducing hypertension and fat and preparation method thereof | |
| CN107648313A (en) | A kind of Western medicine compound for treating obesity and preparation method thereof | |
| CN100345566C (en) | Medicine composition used for reducing weight, prepn. method and use thereof | |
| KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
| CN103719864A (en) | Blood glucose-reducing natto combined capsule and preparation method thereof | |
| CN107136281A (en) | It is a kind of to be used to improve kelp cordyceps sinensis pressed candy of women renal function and preparation method thereof | |
| CN104001157B (en) | Compound preparation of a kind of protect against osteoporosis and preparation method thereof | |
| CN100350954C (en) | Chinese medicine preparation for promoting lead-removal and its preparation process | |
| CN1230191C (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| JP2015050991A (en) | Health supplement | |
| CN105733880A (en) | Composite hazelnut wine brewed from hazelnut meal | |
| CN110507707A (en) | A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes | |
| CN1562253A (en) | Health foods in use for improving symptom in climacteric period of female and fabricating method | |
| KR101930145B1 (en) | Fasting supplement composition | |
| CN110859912A (en) | Traditional Chinese medicine composition for prostatitis and preparation method and application thereof | |
| EP3914237B1 (en) | Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects | |
| CN103948666B (en) | Preparation method of Tibetan medicine for treating diabetes | |
| CN103404875A (en) | Complex ocean special-diet food eaten by patients with cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180202 |
|
| WW01 | Invention patent application withdrawn after publication |